Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology
2007; 17: 253–276.
Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clinical Infectious Diseases
2010; 50: 1439–1447.
Dar L, et al.
Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatric Infectious Diseases Journal
2008; 27: 841–843.
Hamprecht K, et al.
Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet
2001; 357: 513–518.
Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore)
1985; 64: 100–114.
Stagno S, et al.
Breast milk and the risk of cytomegalovirus infection. New England Journal of Medicine
1980; 302: 1073–1076.
Pass RF, et al.
Increased rate of cytomegalovirus infection among parents of children attending day-care centers. New England Journal of Medicine
1986; 314: 1414–1418.
Marshall BC, Adler SP. The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care. American Journal of Obstetrics and Gynecology
2009; 200: 163.e1–163.e5.
Collier AC, et al.
Cytomegalovirus infection in women attending a sexually transmitted disease clinic. Journal of Infectious Diseases
1990; 162: 46–51.
Sohn YM, et al.
Cytomegalovirus infection in sexually active adolescents. Journal of Infectious Diseases
1991; 163: 460–463.
Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Reviews in Medical Virology
2007; 17: 355–363.
Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. Journal of Clinical Virology
2008; 41: 57–62.
Fowler KB, Stagno S, Pass RF. Interval between births and risk of congenital cytomegalovirus infection. Clinical Infectious Diseases
2004; 38: 1035–1037.
Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. Journal of the American Medical Association
2003; 289: 1008–1111.
Townsend CL, et al.
Long term outcomes of congenital cytomegalovirus infection in Sweden and in the United Kingdom. Clinical Infectious Diseases
2013; 56: 1232–1239.
Wang C, et al.
Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clinical Infectious Diseases
2011; 52: e11–e13.
Mussi-Pinhata MM, et al.
Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clinical Infectious Diseases
2009; 15: 522–8.
de Vries JJC, et al.
The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Reviews in Medical Virology
2013; 23: 241–9.
Demmler-Harrison GJ. Congenital cytomegalovirus: public health action towards awareness, prevention, and treatment. Journal of Clinical Virology
2009; 46: S1–S5.
Arvin AM, et al.
Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clinical Infectious Diseases
2004; 39: 233–239.
Lepoutre A, et al.
Seroprevalence of vaccine preventable diseases and of five other infectious diseases in France. Results of two national surveys, 2008–2010.
Bulletin Epidémiologique Hebdomadaire
2013; 41–42: 526–34.
Gratacap-Cavallier B, et al.
Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. European Journal of Epidemiology
1998; 14: 147–152.
Gouarin S, et al.
Congenital HCMV infection: a collaborative and comparative study of virus detection in amniotic fluid by culture and by PCR. Journal of Clinical Virology
2001; 21: 47–55.
Lepage N, et al.
Cytomegalovirus seroprevalence in exposed and unexposed populations of hospital employees. European Journal of Clinical Microbiology and Infectious Diseases
2011; 30: 65–70.
Osborne K, Weinberg J, Miller E. The European Sero-Epidemiology Network (ESEN). Eurosurveillance
1997; 2: 93–96.
Zou G. A modified poisson regression approach to prospective studies with binary data. American Journal of Epidemiology
2004; 159: 702–706.
Korndewal MJ, et al.
Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications. Journal of Clinical Virology
2015; 63: 53–58.
Seale H, et al.
National serosurvey of cytomegalovirus in Australia. Clinical and Vaccine Immunology
2006; 13: 1181–1184.
Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Reviews in Medical Virology
2010; 20: 202–213.
De Ory F, et al.
Is there a change in cytomegalovirus seroepidemiology in Spain?
European Journal of Epidemiology
2004; 19: 85–89.
Lübeck PR, Doerr HW, Rabenau HF. Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed?
Medical Microbiology and Immunology
2010; 199: 53–60.
Forsgren M. Prevention of congenital and perinatal infections. Eurosurveillance
2009; 14: 2–4.
Peckham C, et al.
Screening options for prevention of congenital cytomegalovirus infection. Journal of Medical Screening
2001; 8: 119–24.
Walker S, et al.
Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy and Childbirth
2013; 13: 96.
Schleiss MR, Plotkin SA. Cytomegalovirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 6th edn. Philadelphia: Saunders Elsevier Company, 2013, pp. 1032–1041.
American College of Obstetricians and Gynecologists. Perinatal viral and parasitic infections. ACOG Practice Bulletin 20. International Journal of Gynaecology and Obstetrics
2002; 76: 95–107.
Vauloup-Fellous C, et al.
Does hygiene counselling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. Journal of Clinical Virology
2009; 46(Suppl. 4): S49–S53.
McVoy MA. Cytomegalovirus vaccines. Clinical Infectious Diseases
2013; 57(Suppl.4): S196–S199.